In pooled CORALreef data, patients with eGFR below 60 had a 65.9% placebo-adjusted LDL-C reduction at week 24, with safety comparable to placebo.
|Videos|November 4, 2021
Why Hematuria, Proteinuria Are Associated With Rosuvastatin Use
Jung-Im Shin, MD, PhD, assistant professor at Johns Hopkins University Bloomberg School of Public Health, discusses her presentation at American Society of Nephrology’s Kidney Week 2021 on the known and previously established risks associated with rosuvastatin use.
Advertisement
Pharmacy Times interviewed Jung-Im Shin, MD, PhD, assistant professor at Johns Hopkins University Bloomberg School of Public Health, on her presentation at the American Society of Nephrology’s Kidney Week 2021 on the association of rosuvastatin use with the risk of hematuria and proteinuria.
During the interview, Shin outlined hematuria and proteinuria as well as why they might be associated with rosuvastatin use.
Advertisement
Related to this article
From AKI dosing to CKM therapeutic inertia, experts at ASN Kidney Week 2026 pointed to pharmacists as key to moving new kidney data into practice.
Kidney Week 2026 posters show low-density lipoprotein cholesterol (LDL-C) fell by half in patients receiving dialysis, and oral enlicitide needed no dose adjustment for renal impairment.
Joshua J. Neumiller, PharmD, CDCES, of the American Diabetes Association discusses pharmacists’ role in diabetes and CKD care from ASN Kidney Week 2026
Six-year NATALEE data show adjuvant ribociclib (Kisqali) plus endocrine therapy improves overall survival in high-risk HR+/HER2- early breast cancer, with pharmacist-led monitoring.
Real-world data from ASN Kidney Week show GLP-1 RA users with CKD and obesity had lower rates of kidney failure, death, and heart failure exacerbation.
Hiddo J. L. Heerspink, PharmD, PhD, discusses SOLSTICE elecoglipron data, finerenone in FSGS, and glucagon’s kidney effects from ASN Kidney Week 2026.
Two Kidney Week 2026 analyses tie SGLT2 inhibitors to kidney, CV, and survival gains in T2D, yet over half of patients with diabetic CKD receive neither.
Advertisement
Advertisement
Trending on Pharmacy Times
1
PCSK9 Inhibition Lowers LDL-C in Patients With Kidney Disease
2
The Growing Role the Specialty Pharmacy Team Plays in Helping Breast Cancer Patients Navigate Treatment
3
Kidney Week 2026: Pharmacists' Growing Role in Kidney Care
4
Cystatin C and the Future of Kidney Function Assessment
5